Navigation Links
Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Date:10/13/2008

WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Proteon Therapeutics is presenting new data today representing an important preclinical demonstration of the potential of PRT-201 to enhance outcomes in patients suffering from lower limb peripheral arterial disease (PAD). The presentation, entitled, "Local Catheter-Directed Elastase Therapy: A Novel Approach to Vessel Dilation and Restenosis," is being made at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The new findings are being presented by F. Nicholas Franano, M.D., Chief Scientific Officer of Proteon Therapeutics.

"These preliminary non-clinical results showing vessel dilation with PRT-201 are very exciting," said Timothy P. Noyes, the Company's President and CEO. "We believe that local catheter delivery of PRT-201 immediately following balloon angioplasty procedures could potentially reduce the incidence of restenosis in PAD."

About Peripheral Arterial Disease

Peripheral artery disease, or PAD, is characterized by fatty plaque build-up in the arteries of the legs, which leads to poor blood flow and circulation. According to the American Heart Association, PAD affects eight million Americans and is a significant cause of both morbidity and death. Patients with PAD may experience muscle pain during walking, have wounds and ulcers that are slow to heal or, in the most severe cases, require amputation of the legs. Current interventional procedures, such as balloon angioplasty, are inadequate due to high rates of restenosis that restricts blood flow following treatment of the diseased vessel segments.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue r
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
4. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
5. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Back in the 1970’s, many companies calculated their office ... included space for circulation and file storage. “It was ... Nidea Corporate Real Estate / ITRA Global , a ... however, 250 square feet per employee became the norm. ... 175 to 225 square feet, and over the next few ...
(Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
(Date:9/29/2014)... Research and Markets  has announced the ... & Services, End-User , Application - Global Forecast to ... The global oligonucleotide synthesis market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... the basis of products and services, applications, end users, ...
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
Breaking Biology Technology:ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2
... CAMBRIDGE, Mass., Jan. 13 Verenium Corporation,(Nasdaq: ... the development of next-generation cellulosic,ethanol and high-performance ... compliance with the continued listing requirements of ... that it had fallen out of,compliance with ...
... January 15th at 1:00PM PTNEW YORK, Jan. 13 ... announced that Michael S. Weiss, the Company,s Chairman and ... J.P. Morgan 27th Annual Healthcare Conference being held in ... Thursday, January 15th at 1:00pm PT and will be ...
... Jan. 13 Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... The agreement is Burnham,s first broad-based partnership ... agreement, Burnham will provide J&JPRD with access ...
Cached Biology Technology:Verenium Regains Compliance With Nasdaq Continued Listing Requirement 2Verenium Regains Compliance With Nasdaq Continued Listing Requirement 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... 2008The 2008 American Society for Microbiology (ASM) BD ... presented to Stephen C. Edberg, Professor, Department of ... of Medicine, and Director, Clinical Microbiology Laboratory, Yale-New ... award recognizes a distinguished scientist for research accomplishments ...
... be the first recipient of a prestigious award given by ... Meeting of the Ecological Society of America on August 3. ... an outstanding record of informing their political decision-making with ecological ... figure that has a sharp appreciation for local and global ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... is presented to Steven A. Rosenberg, Chief of ... Services University of the Health Sciences, and Professor ... and Health Sciences. Sponsored by Abbott Laboratories Diagnostics ...
Cached Biology News:American Society for Microbiology honors Stephen C. Edberg 2American Society for Microbiology honors Steven A. Rosenberg 2
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Phospho-p70 S6 Kinase (T229) Affinity Purified PAb...
Biology Products: